Impact of investment losses at equity-method affiliates on ordinary loss
First written in FY2020-Q2. 10 of 16 entries say "Worsened", first in FY2020-Q3. Latest entry: FY2025.
Immuno-Biological Laboratories moved to the "Worse" side of this theme in 2020, 2 years before the typical company in this theme (2022).
The whole theme swung hardest in 2023: 19 of 68 companies on the "Worse" side.
31 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「As the impact of equity-method investment losses at associates ceased from the current consolidated fiscal year onward, with ¥203.844 million recorded in the previous fiscal year, among other factors, ordinary loss of ¥149.503 million in the previous fiscal year turned into ordinary profit of ¥125.413 million in the current fiscal year.」
The absence of the impact of equity-method investment losses continued throughout the fiscal year, contributing to a return to profitability in ordinary income. - FY2024MitigatedAnnual report
「As the impact of equity-method investment losses at associates ceased from the current consolidated fiscal year onward, with ¥203.844 million recorded in the previous fiscal year, among other factors, ordinary loss of ¥149.503 million in the previous fiscal year turned into ordinary profit of ¥125.413 million in the current fiscal year.」
Following the partial transfer of CURED shares and its exclusion from equity-method accounting, no equity-method investment loss was recorded in the current fiscal year, eliminating the ¥203.844 million burden recorded in the previous year. - FY2024-Q2MitigatedAnnual report
「Loss on investments accounted for under the equity method 90,359 —」
The ¥90.359 million loss on investments accounted for under the equity method recorded in the same period of the previous year was not recorded in the cumulative second quarter under review. Following the partial transfer of CURED shares and its exclusion from equity-method accounting, the impact of losses on investments in associates has remained limited. - FY2024-Q1MitigatedAnnual report
「As the impact of equity-method investment losses and other factors at an associate, which had had a significant impact on earnings in the previous fiscal year, was limited, ordinary loss of ¥54.731 million in the previous year turned into ordinary profit of ¥13.517 million, while the quarterly net loss attributable to owners of the parent of ¥58.937 million in the previous year turned into quarterly net income attributable to owners of the parent of ¥11.165 million.」
The impact of equity-method investment losses and other factors, which had had a significant impact in the previous fiscal year, was limited in the first quarter under review, resulting in a return to profitability in ordinary income and net income. - FY2023-Q3MitigatedAnnual report
「As the business relationship between the group and CURED Co. had become less significant, and to minimize external effects, the group decided to transfer part of its shares in CURED Co. and exclude the company from its associates accounted for under the equity method.」
The equity-method investment loss decreased to ¥96.557 million from ¥103.868 million in the same period of the previous year. In addition, a policy was decided to exclude CURED Co. from associates accounted for under the equity method through the partial transfer of its shares. - FY2023-Q2WorsenedAnnual report
「In addition, ordinary loss was ¥129.668 million, compared with ordinary loss of ¥188.170 million in the same period of the previous year, mainly because the company recorded ¥90.359 million in equity-method investment losses on an associate as a non-operating expense.」
The loss on investments accounted for under the equity method increased to ¥90.359 million from ¥57.180 million in the same period of the previous year. Although total ordinary loss narrowed, the burden of losses on investments in associates increased. - FY2023-Q1WorsenedAnnual report
「In addition, ordinary loss was ¥54.731 million, compared with ordinary loss of ¥101.640 million in the same period of the previous year, mainly because the company recorded ¥49.199 million in equity-method investment losses on an associate as a non-operating expense.」
The loss on investments accounted for under the equity method increased to ¥49.199 million from ¥32.319 million in the same period of the previous year. Although total ordinary loss narrowed, the burden of losses on investments in associates increased. - FY2022-Q3WorsenedAnnual report
「The company recorded an equity-method investment loss of ¥103.868 million relating to an affiliate as a non-operating expense, among other items. As a result, the ordinary loss was ¥232.900 million, compared with an ordinary loss of ¥299.846 million in the same period of the previous year.」
The loss on investments accounted for under the equity method increased to ¥103.868 million from ¥70.059 million in the same period of the previous year. The company explained that the investment loss includes losses such as research and development costs incurred by associates CURED and AI BIO. - FY2022-Q2WorsenedAnnual report
「The company recorded an equity-method investment loss of ¥57.180 million relating to an affiliate as a non-operating expense, among other items. As a result, the ordinary loss was ¥188.170 million, compared with an ordinary loss of ¥227.918 million in the same period of the previous year.」
The equity-method investment loss relating to an affiliate increased from ¥49.324 million in the same period of the previous year to ¥57.180 million. Although the overall ordinary loss narrowed, the burden of investment losses at affiliates increased. - FY2022-Q1WorsenedAnnual report
「The company recorded an equity-method investment loss of ¥32.319 million relating to an affiliate as a non-operating expense, among other items. As a result, the ordinary loss was ¥101.640 million, compared with an ordinary loss of ¥127.681 million in the same period of the previous year.」
The equity-method investment loss increased from ¥26.392 million in the same period of the previous year to ¥32.319 million, contributing to the ordinary loss. - FY2021-Q3WorsenedAnnual report
「The company recorded an equity-method investment loss of ¥70.059 million relating to an affiliate as a non-operating expense, among other items. As a result, the ordinary loss was ¥299.846 million, compared with an ordinary loss of ¥350.212 million in the same period of the previous year.」
The equity-method investment loss increased from ¥64.170 million in the same period of the previous year to ¥70.059 million. Although the overall ordinary loss narrowed, the burden of investment losses at affiliates increased. - FY2021-Q2WorsenedAnnual report
「The company recorded an equity-method investment loss of ¥49.324 million relating to an affiliate as a non-operating expense, among other items. As a result, the ordinary loss was ¥227.918 million, compared with an ordinary loss of ¥252.326 million in the same period of the previous year.」
The equity-method investment loss increased from ¥40.103 million in the same period of the previous year to ¥49.324 million. Although the overall ordinary loss narrowed year on year, the burden of investment losses at affiliates increased. - FY2021-Q1WorsenedAnnual report
「The company recorded an equity-method investment loss of ¥26.392 million relating to an affiliate as a non-operating expense, among other items. As a result, the ordinary loss was ¥127.681 million, compared with an ordinary loss of ¥127.850 million in the same period of the previous year.」
The equity-method investment loss increased from ¥19.947 million in the same period of the previous year to ¥26.392 million. The ordinary loss was broadly unchanged year on year, but the burden of investment losses at affiliates continued. - FY2020WorsenedAnnual report
「The company recorded an equity-method investment loss of ¥94.290 million, among other items. As a result, the ordinary loss was ¥678.762 million, compared with an ordinary loss of ¥155.747 million in the same period of the previous year.」
Investment losses relating to equity-method affiliates, including CURED, totaled ¥94.290 million and contributed to the widening of the ordinary loss from ¥155.747 million in the previous year to ¥678.762 million. - FY2020-Q3WorsenedAnnual report
「Non-operating income and expenses included an equity-method investment loss of ¥64.170 million. As a result, the ordinary loss was ¥350.212 million, compared with an ordinary loss of ¥62.866 million in the same period of the previous year.」
The equity-method investment loss was ¥64.170 million, up from ¥40.103 million in the previous disclosure. Although the company recorded extraordinary gains, including a ¥15.917 million gain on the sale of shares in an affiliate, the ordinary loss widened to ¥350.212 million. - FY2020-Q2First statedAnnual report
「Non-operating income and expenses included an equity-method investment loss of ¥40.103 million. As a result, the ordinary loss was ¥252.326 million, compared with an ordinary loss of ¥32.924 million in the same period of the previous year.」
The company newly recorded an equity-method investment loss of ¥40.103 million, which contributed to the ordinary loss of ¥252.326 million.